Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers

General Physiology and Biophysics

Volumn 28, Issue 3, 2009, Pages 309-315

  Štětinová, Ěra ^a   Smetanová, Libuše ^a   Kholová, Dagmar ^a   Svoboda, Zbyněk ^a   Květina, Jaroslav ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Ambroxol; Biopharmaceutics Classification System; Caco 2 cells; Transport

Indexed keywords

AMBROXOL;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; DIFFUSION; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PH; PHARMACOKINETICS; SOLUBILITY;

ABSORPTION; AMBROXOL; CALCIUM; CARCINOMA; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; EPITHELIUM; EXPECTORANTS; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LINEAR MODELS; MODELS, BIOLOGICAL; PERMEABILITY; SOLUBILITY; ULTRAVIOLET RAYS;

EID: 72949102068     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2009_03_309     Document Type: Article

References (28)

1. Amidon G. J., Lennernäs H., Shah V. P., Crison J. R. (1995): A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420; doi:10.1023/A:1016212804288
2. Artursson P., Karlsson J. (1991): Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175,880-885; doi:10.1016/0006-291X(91)91647-U
3. Artursson P., Palm K., Luthman K. (2001): Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46,27-43; doi: 10.1016/S0169-409X(00)00128-129
4. Artursson R, Bergström C. A. S. (2004): Intestinal absorption: the role of polar surface area. In: Drug Bioavailability. (Eds. H. Waterbeemd, H. Lennernäs and P. Artursson), pp. 341-357, (2nd edition), Wiley-Vch. Verlag GmbH&Co. KGaA, Weinheim
5. Baird A. W., Presser E. S. (1998): Cell culture models for polarized epithelial monolayers. In: Animal Cell Culture Techniques. (Ed. M. Clynes), pp. 298-318, Springer-Verlag, Berlin - Heidelberg-New York
6. Bourdet D. L., Thakker D. R. (2006): Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein. Pharm. Res. 23, 1165-1177; doi:10.1007/s11095-006-0251-4
7. Delie F., Rubas W. (1997): A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit. Rev. Ther. Drug Carrier Syst. 14,221-286
8. Disse B. G. (1987): The pharmacology of ambroxol - review and new results. Eur. J. Respir. Dis. 71,255-262
9. Fleet J. C., Wood R. J. (1999): Specific 1,25(OH)2D3-mediated regula- tion of transcellular calcium transport in Caco-2 cells. Am. J. Physiol., Gastrointest. Liver Physiol. 276, G958-964
10. Garcia-Casal M. N., Leets I., Layrisse M. (2000): β-carotene and inhibitors of iron absorption modify iron uptake by Caco- 2 cells. J. Nutr. 130, 5-9
11. Hammer R., Bozler G., Jauch R., Koss F. W. (1978): Ambroxol, comparative studies of pharmacokinetics and biotransformation in rat, rabbit, dog and man. Arzneim.-Forsch. 28, 899-903 (in German)
12. Hidalgo I. J., Raub T. J., Borchardt R. T. (1989): Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96, 736-749
13. Ingels F. M., Augustijns P. F. (2003): Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. J. Pharm. Sci. 92,1545-1558; doi: 10.1002/jps. 10408
14. Lennernäs H., Palm K., Fagerholm U., Artursson P. (1996): Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127, 103-107; doi: 10.1016/0378-5173(95)04204-0
15. Malerba M., Ragnoli B. (2008): Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin. Drug Metab. Toxicol. 4, 1119-1129; doi:10.1517/ 17425255.4.8.1119
16. McMillan J. M., Walle U. K., Walle T. (2005): S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J. Pharm. Pharmacol. 57,599-605; doi: 10.1211 /0022357056082
17. Polli J. E., Yu L. X., Cook J. A., Amidon G. L., Borchardt R. T., Burnside B. A., Burton P. S., Chen M. L., Conner D. P., Faustino P. J., Hawi A. A., Hussain A. S., Joshi H. N., Kwei G., Lee V. H. L., Lesko L. J., Lipper R. A., Loper A. E., Nerurkar S. G., Polli J. W, Sanvordeker D. R., Taneja R., Uppoor R. S., Vattikonda C. S., Wilding I., Zhang G. (2004): Summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities. J. Pharm. Sci. 93, 1375-1381; doi:10.1002/jps.20064
18. Püschmann S., Engelhorn R. (1978): Pharmacological study on the bromhexine metabolite ambroxol. Arzneim.-Forsch. 28, 889-898 (in German)
19. Su F., Wang. F., Gao W., Li H. (2007): Determination of ambroxol in human plasma by high performance liquid chromatography-electrospray ionization mass spektrometry (HPLC-MS/ESI). J. Chromatogr., B: Biomed. Appl. 853, 364-368; doi: 10.1016/j.jchromb.2007.03.015
20. Štětinová V., Herout V., Květina J. (2004): In vitro and in vivo antioxidant activity of ambroxol. Clin. Exp. Med. 4, 152-158; doi: 10.1007/s 10238-004-0050-53
21. Ungell A.-L., Karlsson J. (2004): Cell culture in drug discovery: an industrial perspective. In: Drug Bioavailability. (Eds. H. Waterbeemd, H. Lennernās and P. Artursson), pp. 90-131, (2nd edition), Wiley-Vch. Verlag GmbH&Co. KGaA, Weinheim
22. Vachon P. H., Beaulieu J.-F. (1992): Transient mosaic patterns of morphological and functional differentiation in the Caco- 2 cell line. Gastroenterology 103, 414-423
23. Vergin H., Bishop-Freundling G. B., Miczka M., Nitsche V., Strobel K., Matzkies F. (1985): The pharmacokinetics and bioequivalence of various dosage forms of ambroxol. Arzneim.-Forsch. 35,1591-1595 (in German) (Pubitemid 16236133)
24. Van de Waterbeemd H. (2005): Which in vitro screens guide the prediction of oral absorption and volume of distribution? Basic Clin. Pharmacol. Toxicol. 96,162-166; doi:10.1111/ j.1742-7843.2005.pto960304.x
25. Wu C.-Y., Benet L. Z. (2005): Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22,11-23; doi:10.1007/s11095-004-9004-4
26. Walle U. K., Walle T. (1998): Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab. Dispos. 26, 343-346
27. Yazdanian M., Briggs K., Jankovsky C., Hawi A. (2004): The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 21,293-299; doi: 10.1023/B:PHAM.0000016242.48642.71
28. Yee S. (1997): In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in manfact or myth. Pharm. Res. 14, 763-766; doi:10.1023/A:1012102522787